Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis?

CHRISTOPH TAPPEINER, CARSTEN HEINZ, GЕRD GANSER and ARND HEILIGENHAUS

J Rheumatol 2012;39;1294-1295
http://www.jrheum.org/content/39/6/1294.2

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprintsPermissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis?

To the Editor:

Anti-interleukin 6 receptor (anti-IL-6R) antibodies have been effective in experimental models of autoimmune arthritis, encephalomyelitis, and also uveitis1,2. Tocilizumab (TCZ; RoActemra®, Hoffmann-La Roche, Basel, Switzerland), a fully humanized anti-IL-6R antibody, has been approved for the treatment of rheumatoid arthritis. Efficacy has also been shown for systemic-onset juvenile idiopathic arthritis (JIA)3 and vasculitis4. To date, however, no reports have appeared concerning its efficacy in JIA-associated uveitis.

In about one-third of JIA patients with uveitis, eye inflammation runs a severe course and vision-threatening complications develop, and immunosuppressive treatment is required. Because some patients do not respond properly to the widely used disease-modifying antirheumatic drugs (DMARD), including tumor necrosis factor-α (TNF-α) inhibitors, there is a significant need for alternative treatment options. We describe our initial experience with TCZ for treatment of JIA-associated uveitis at a tertiary uveitis and pediatric rheumatology referral center.

Three adult patients (mean age 18.3 yrs) with JIA-associated chronic anterior uveitis (mean duration 8 yrs, range 4–13) with insidious onset of flare and the presence of vision-threatening complications (Table 1) were treated with intravenous TCZ 8 mg/kg body weight at 4-weekly intervals5. Written informed consent was obtained from patients for off-label use of TCZ. In all patients the disease had been refractory to high dosages of topical corticosteroids and systemic immunosuppression. Dosages were within generally used ranges, e.g., for methotrexate (MTX) 15 mg/m², azathioprine (AZA) 2 mg/kg body weight, adalimumab (ADA) 40 mg biweekly, etanercept (ETA) 0.8 mg/kg body weight weekly, abatacept (ABA) 10 mg/kg body weight monthly.

Response to treatment in adult patients with juvenile idiopathic arthritis (JIA)-associated uveitis treated with tocilizumab (TCZ) when refractory to topical corticosteroids and systemic immunosuppression.

Table 1. Adult patients with juvenile idiopathic arthritis (JIA)-associated uveitis were treated with tocilizumab when refractory to topical corticosteroids and systemic immunosuppression.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age/sex</th>
<th>ILAR Classification</th>
<th>HLA-B27/ANA/RF</th>
<th>JIA Diagnosis at Age, yrs</th>
<th>Uveitis Diagnosis at Age, yrs</th>
<th>Uveitis Type**</th>
<th>Involved Eyes</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>18 M</td>
<td>Oligoarthritis, ext.</td>
<td>Neg/pos/neg</td>
<td>4</td>
<td>5</td>
<td>Anterior</td>
<td>Both</td>
<td>Cataract, synchiae, glaucoma</td>
</tr>
<tr>
<td>2</td>
<td>18 F</td>
<td>Polyarthritis</td>
<td>Neg/pos/neg</td>
<td>11</td>
<td>11</td>
<td>Anterior</td>
<td>Both</td>
<td>Cataract, synchiae</td>
</tr>
<tr>
<td>3</td>
<td>19 F</td>
<td>Polyarthritis</td>
<td>Neg/pos/neg</td>
<td>3</td>
<td>15</td>
<td>Anterior</td>
<td>Left</td>
<td>Cataract, synchiae, macular edema, glaucoma</td>
</tr>
</tbody>
</table>

* At time of starting tocilizumab therapy. ** Standardization of Uveitis Nomenclature classification7. ANA: antinuclear antigen; RF: rheumatoid factor; ILAR: International League of Associations for Rheumatology.

Table 2. Response to treatment in adult patients with juvenile idiopathic arthritis (JIA)-associated uveitis treated with tocilizumab (TCZ) when refractory to topical corticosteroids and systemic immunosuppression. Dosages were within generally used ranges, e.g., for methotrexate (MTX) 15 mg/m², azathioprine (AZA) 2 mg/kg body weight, adalimumab (ADA) 40 mg biweekly, etanercept (ETA) 0.8 mg/kg body weight weekly, abatacept (ABA) 10 mg/kg body weight monthly.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Treatment Prior to TCZ</th>
<th>Uveitis Activity† After TCZ</th>
<th>Months Until Inactive</th>
<th>Sparing of Other Immunosuppressives After TCZ**</th>
<th>Steroid Eye Drops Before/After TCZ (n = times daily)</th>
<th>Uveitis Recurrence After TCZ (followup, mo)</th>
<th>Arthritis Activity†† Prior to TCZ</th>
<th>Arthritis Activity†† After TCZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PRED*, MTX*, ETA, ADA, ABA*</td>
<td>Active</td>
<td>—</td>
<td>No</td>
<td>5/7</td>
<td>Ongoing; 8</td>
<td>Yes</td>
<td>Improved</td>
</tr>
<tr>
<td>2</td>
<td>PRED*, MTX*, ETA, ADA*</td>
<td>Inactive</td>
<td>1</td>
<td>No</td>
<td>4/2</td>
<td>No; 12</td>
<td>Yes</td>
<td>Improved</td>
</tr>
<tr>
<td>3</td>
<td>PRED*, AZA*, MTX, ETA, ADA*</td>
<td>Inactive</td>
<td>1</td>
<td>No</td>
<td>3/1</td>
<td>No; 6</td>
<td>Yes</td>
<td>Improved</td>
</tr>
</tbody>
</table>

† Uveitis activity determined according to SUN criteria7. †† Arthritis activity determined by PedACR30/50/70 criteria8. Pred: prednisolone; SUN: Standardization of Uveitis Nomenclature.
REFERENCES


J Rheumatol 2012;39:6; doi:10.3899/jrheum.120010